Lee’s Pharma Adds Financial Detail to Discloseable Asset Acquisition

Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ) just unveiled an update.

Lee’s Pharmaceutical Holdings Limited has issued a supplemental announcement regarding its previously disclosed acquisition of certain assets, providing additional financial details on the purchased portfolio. The company reported that the acquired assets generated revenue of US$4.584 million and gross profit of US$3.997 million in 2023, and revenue of US$3.217 million and gross profit of US$511,000 in 2024, based on the seller’s audited financial statements. Management noted it is impracticable to determine net profit or loss attributable to the assets because certain expenses relate to excluded items not forming part of the acquisition, but emphasized that this additional disclosure does not alter other terms or information previously announced about the transaction, offering investors more clarity on the historical performance of the acquired business components.

The most recent analyst rating on (HK:0950) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Lee’s Pharmaceutical Holdings Limited stock, see the HK:0950 Stock Forecast page.

More about Lee’s Pharmaceutical Holdings Limited

Lee’s Pharmaceutical Holdings Limited is a Hong Kong–listed company (Stock Code: 950) incorporated in the Cayman Islands with limited liability. The board comprises executive, non-executive and independent non-executive directors, reflecting a typical governance structure for a diversified pharmaceutical group, though this announcement does not detail its specific product lines or therapeutic focuses.

Average Trading Volume: 2,109,747

Technical Sentiment Signal: Sell

Current Market Cap: HK$977.5M

For detailed information about 0950 stock, go to TipRanks’ Stock Analysis page.